Bank of America Securities analyst Travis Steed maintained a Buy rating on Medtronic (MDT – Research Report) today. The company’s shares opened ...

Medtronic's Q2 results beat Wall Street expectations, with revenue up 5% year-over-year. Click here to find out why I have a ...

Medtronic (NYSE:MDT – Free Report) had its price objective decreased by Wells Fargo & Company ... Its Cardiovascular ...

NORTHAMPTON, MA / ACCESSWIRE / November 21, 2024 /By Ken Washington, Chief Technology and Innovation Officer, and Raman Venkatesh, Chief Sustainability Officer, MedtronicWhen you think about healthcar ...

Pathstone Holdings LLC lowered its stake in Medtronic plc (NYSE:MDT – Free Report) by 3.2% during the third quarter, ...

Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Medtronic (MDT) to $98 from $106 and keeps an Overweight rating on the ...

I'm Ryan Weispfenning, vice president and head of Medtronic investor relations ... performance from franchises like TAVR, PFA, leadless pacemakers, diabetes, spine, and neuromodulation, just ...

Presentation Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations at Medtronic Good morning. I'm Ryan ...

Medtronic plc (NYSE: MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024.

Here's a look at Medtronic's past performance and the resulting price change ... Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices ...